Marinomed Biotech AG Agrees to Sell Carragelose Business to Unither Pharmaceuticals

Marinomed Biotech AG, based in Korneuburg, Austria, has entered into an agreement to sell its Carragelose business to Unither Pharmaceuticals. Unither, a French CDMO specializing in medical devices and pharmaceuticals, will make upfront and milestone payments totaling up to EUR 20 million. These payments are contingent on specific commercial and operational achievements over a two-year period.

The transaction includes a transition service agreement between Marinomed and Unither. Proceeds from the sale will support Marinomed's ongoing operations, particularly its Marinosolv platform, and contribute to the company's recently announced restructuring plan.

Completion of this sale is dependent on successful restructuring, along with approval from Marinomed's Supervisory Board and shareholders during an extraordinary general meeting.